Clinical Trials Directory

Trials / Terminated

TerminatedNCT03709693

Clinical Outcomes in Patients Treated With SternaLock Blu

Sternal Rigid Fixation: Evaluation of Clinical Outcomes Using Real-World Evidence

Status
Terminated
Phase
Study type
Observational
Enrollment
156 (actual)
Sponsor
Zimmer Biomet · Industry
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

The primary objective of this study is to evaluate the rate of deep sternal wound infection at 30 days post-operative following a full median sternotomy in patients treated with SternaLock Blu for rigid sternal fixation. This study will also provide evidence of the clinical performance of SternaLock Blu for up to 90 days using real world evidence methodology. Sternal complications will be reported through 90 days follow up.

Detailed description

The primary endpoint for this study is the rate of deep sternal wound infection (DSWI) at 30 days post-operative, following a midline sternotomy closed with SternaLock Blu. DSWI is defined as deep infection involving muscle, bone, and/ or mediastinum requiring operative intervention and has all of the following conditions: 1. Wound opened with excision of tissue or re-exploration of mediastinum 2. Positive culture unless patient on antibiotics at the time of culture or no culture obtained 3. Treatment with antibiotics beyond perioperative prophylaxis Post-operative sternal wound complications occurring within 90 days post-operative. Outcomes will be reported up to 90 days after surgery, including data on adverse events associated with the use of SternaLock Blu Sternal Closure System from the moment of implantation to the end-of-study.

Conditions

Interventions

TypeNameDescription
DEVICESternaLock BluSternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.

Timeline

Start date
2019-05-14
Primary completion
2020-05-13
Completion
2020-05-13
First posted
2018-10-17
Last updated
2021-07-23

Locations

4 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03709693. Inclusion in this directory is not an endorsement.